Abstract
We report the case of an HIV-positive patient with visceral leishmaniasis and several relapses after treatment with the two first-line anti-leishmanial drugs, liposomal amphotericin B and miltefosine. End-stage renal failure occurred in 2007 when the patient was on long-term treatment with miltefosine. A relapse of leishmaniasis in 2008 was successfully treated with a novel combination regimen of intravenous pentamidine and oral fluconazole. Secondary prophylaxis with fluconazole monotherapy did not prevent parasitological relapse of leishmaniasis.
Copyright 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
AIDS-Related Opportunistic Infections / complications
-
AIDS-Related Opportunistic Infections / drug therapy*
-
Administration, Oral
-
Antiprotozoal Agents / administration & dosage
-
Antiprotozoal Agents / therapeutic use*
-
Drug Therapy, Combination
-
Fluconazole / administration & dosage
-
Fluconazole / therapeutic use*
-
HIV Seropositivity / complications
-
Humans
-
Injections, Intravenous
-
Kidney Failure, Chronic / complications
-
Leishmania donovani*
-
Leishmaniasis, Visceral / drug therapy*
-
Leishmaniasis, Visceral / etiology
-
Male
-
Middle Aged
-
Pentamidine / administration & dosage
-
Pentamidine / therapeutic use*
Substances
-
Antiprotozoal Agents
-
Pentamidine
-
Fluconazole